Targeted agents for the treatment of advanced renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Renal cell carcinoma (RCC) is a treatment-resistant cancer with complex molecular underpinnings.
• Mutations in the von Hippel-Lindau (VHL) gene drive clear-cell RCC by upregulating pro-tumorigenic factors like VEGF, bFGF, and PDGF, promoting angiogenesis.
• VHL gene mutations also increase tumor cell proliferation through Carbonic anhydrase IX and epidermal growth factor receptor (EGFR) signaling.

Purpose of the Study:

• To review the molecular targets and therapeutic agents being developed for renal cell carcinoma.
• To explore the role of intracellular signaling pathways, including PI3K and Raf/MEK/ERK, in RCC.
• To discuss the potential of combination therapies for enhanced anti-tumor activity in RCC.

Main Methods:

• Review of current research on molecular targets in RCC, including VHL gene mutations and associated signaling pathways.
• Identification and categorization of therapeutic agents targeting key molecular pathways such as VEGF, PDGF, and EGFR.
• Analysis of intracellular signaling cascades (PI3K, Raf/MEK/ERK) and their relevance to RCC treatment.

Main Results:

• Numerous agents targeting VEGF, VEGF receptors, PDGF receptors, and EGFR are in development.
• Intracellular pathways like Raf/MEK/ERK and PI3K are targeted by specific agents (e.g., BAY 43-9006, CCI-779).
• Other targets include the G250 antigen (WX-G250) and the 26S proteasome (PS-341).

Conclusions:

• Targeting multiple pathways simultaneously or in combination may enhance anti-tumor efficacy in RCC.
• The development of novel agents offers new therapeutic avenues for this resistant cancer.
• Combination strategies hold promise for overcoming treatment resistance by inhibiting multiple contributing pathways.